/
/
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
A subscription to JoVE is required to view this content. Sign in or start your free trial.
1Department of Cell Biology, School of Basic Medical Sciences,Nanjing Medical University, 2Institute for Brain Tumors & Key Laboratory of Rare Metabolic Diseases,Nanjing Medical University; Nanjing Medical University Affiliated Cancer Hospital; Key Laboratory of Human Functional Genomics of Jiangsu Province
Chapters
- 00:04Introduction
- 00:47Preparing Luciferase-tagged GSCs
- 02:19Combination Screening
- 03:51Results: Identification of Potential Combination Therapy Candidates for Glioblastoma
- 05:02Conclusion
The glioma stem cells (GSCs) are a small fraction of cancer cells which play essential roles in tumor initiation, angiogenesis, and drug resistance in glioblastoma (GBM), the most prevalent and devastating primary brain tumor. The presence of GSCs makes the GBM very refractory to most of individual targeted agents, so high-throughput screening methods are required to identify potential effective combination therapeutics. The protocol describes a simple workflow to enable rapid screening for potential combination therapy with synergistic interaction. The general steps of this workflow consist of establishing luciferase-tagged GSCs, preparing matrigel coated plates, combination drug screening, analyzing, and validating the results.
